Lilly pumps up Aussie radio deal

Posted 13 February 2025 AM 

Eli Lilly has seen potential in AdvanCell and expanded the scope and breadth of an existing strategic collaboration originally inked by Point Biopharma to advance novel radiopharmaceuticals for various cancers.

The Aussie clinical-stage radiopharmaceutical company’s therapeutic pipeline is powered by alpha 212, which is the isotope of Lead-212 (Pb-212) – and is led by a would-be challenger to Novartis prostate cancer drug Pluvicto. AdvanCell’s portfolio also comprises targeted alpha therapies for melanoma, pancreatic, and breast cancer.